Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) have received an average rating of “Hold” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $37.00.
Several research analysts have recently weighed in on RHHBY shares. ValuEngine lowered Roche Holdings AG Basel from a “hold” rating to a “sell” rating in a research report on Tuesday, September 10th. UBS Group raised Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research note on Friday, July 26th.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Colony Group LLC bought a new position in Roche Holdings AG Basel in the 2nd quarter valued at $6,887,000. Schafer Cullen Capital Management Inc boosted its holdings in shares of Roche Holdings AG Basel by 10.9% in the 2nd quarter. Schafer Cullen Capital Management Inc now owns 1,953,425 shares of the company’s stock worth $65,127,000 after buying an additional 192,360 shares during the last quarter. Douglass Winthrop Advisors LLC boosted its holdings in shares of Roche Holdings AG Basel by 19.8% in the 3rd quarter. Douglass Winthrop Advisors LLC now owns 764,226 shares of the company’s stock worth $27,856,000 after buying an additional 126,248 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Roche Holdings AG Basel by 1.7% during the second quarter. Parametric Portfolio Associates LLC now owns 5,499,135 shares of the company’s stock valued at $193,020,000 after buying an additional 91,821 shares during the period. Finally, Meritage Portfolio Management grew its position in Roche Holdings AG Basel by 382.1% during the third quarter. Meritage Portfolio Management now owns 90,048 shares of the company’s stock valued at $3,282,000 after buying an additional 71,370 shares during the period. Hedge funds and other institutional investors own 0.32% of the company’s stock.
Shares of RHHBY traded up $0.27 during mid-day trading on Friday, reaching $38.30. 1,532,968 shares of the company were exchanged, compared to its average volume of 917,142. Roche Holdings AG Basel has a 52 week low of $29.45 and a 52 week high of $38.32. The stock has a market capitalization of $257.02 billion, a PE ratio of 16.51, a PEG ratio of 2.34 and a beta of 0.50. The business has a 50 day simple moving average of $36.80 and a two-hundred day simple moving average of $34.87.
About Roche Holdings AG Basel
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Read More: Why do companies issue monthly dividends?
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.